Serum endostatin levels in patients with epithelial ovarian cancer

Anticancer Research

Volumn 23, Issue 2 C, 2003, Pages 1907-1912

  Hata, Kohkichi ^a   Kumar Dhar, Dipok ^a   Kanasaki, Haruhiko ^a   Nakayama, Kentaro ^a   Fujiwaki, Ristuto ^a   Katabuchi, Hidetaka ^b   Okamura, Hitoshi ^b   Nagasue, Naofumi ^a   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Endostatin; Epithelial ovarian cancer; Prognostic factor; Serum levels

Indexed keywords

ENDOSTATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OVARY CARCINOMA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COLLAGEN; COLLAGEN TYPE XVIII; ENDOSTATINS; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS;

EID: 0038538455     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
2. Boehm T, Folkman J, Browder T and O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407, 1997.
3. Standker L, Schrader M, Kanse SM, Jurgerns M, Forssmann W-G and Preissner KT: Isolation and characterization of the circulating form of human endostatin. FEBS Lett 420: 129-133, 1997.
4. Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR and Timpl R: Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 17: 4249-4256, 1988.
5. Taddei L, Chiarugi P, Brogelli L, Cirri P, Magnelli L, Raugei G, Ziche M, Granger HJ, Chiarugi V and Ramponi G: Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem Biophys Res Commun 263: 340-345, 1999.
6. Hata K, Fujiwaki R, Nakayama K and Miyzaki K: Expression of the endostatin gene in epithelial ovarian cancer. Clin Cancer Res 7: 2405-2409, 2001.
7. Hefler L, Tempfer C, Kainz C and Obermair A: Serum concentration of endostatin in patients with vulvar cancer. Gynecol Oncol 74: 151-152, 1999.
8. Shaarawy M and EI-Sharkawy SA: Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer. Acta Oncol 40: 513-518, 2001.
9. Yamagata M, Shiratori Y, Dan Y, Shiina S, Takayama T, Makuuchi M and Omata M: Serum endostatin levels in patients with hepatocellular carcinoma. Ann Oncol 11: 761-762, 2000.
10. Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Turner EM, Alexander HR Jr and Libutti SK: Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 6: 4628-4634, 2000.
11. Feldman AL, Pak H, Yang JC, Alexander HR Jr and Libutti SK: Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 91: 1525-1529, 2001.
12. International Federation of Gynecology and Obstetrics (FIGO): Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156: 263-264, 1987.
13. Preston DL, Lubin JH and Pierce DA: EPICURE: risk regression and data analysis software. Seattle, HiroSoft International Corporation, 1990.
14. Serov SF, Scully RE and Sobin LH: International Histological Classification of Tumours, No. 9: Histological Typing of Ovarian Tumours. Geneva, World Health Organization, 1973.
15. Arao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, Nomura H, Hiai H and Fukumoto M: Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 54: 1355-1359, 1994.
16. Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, Lhomme C, Scherer C, Tigaud J-D, Benchaib M, Fourme E, Castaigne D, Querleu D and Dargent D: Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 91: 2329-2334, 2001.
17. Beale PJ and Friedlander ML: Prognostic variables in ovarian cancer. In: Epithelial Cancer of the Ovary (Lawton FG, Neijt JP, and Swenerton KD, eds). London, BMJ Publishing Group, 1995, pp 96-111.
18. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
19. Sugarbaker EV, Thornthwaite J and Ketcham AS: Inhibitory effect of a primary tumor on metastasis. In: Progress in Cancer Research and Therapy (Day SB, Myers PL, Stansly P, Garattini S and Lewis MG, eds). New York, Raven Press, 1977, pp 227-240.
20. Warren BA, Chauvin WJ and Philips J: Blood-borne tumor emboli and their adherence to vessel wall. In: Progress in Cancer Research and Therapy (Day SB, Myers PL, Stansly P, Garattini S and Lewis MG, eds). New York, Raven Press, 1977, pp 185-197.
21. Clark WH Jr, Elder DE, Guerry DI, Braitman LE, Trock BJ, Schuitz D, Synnestevdt M and Halpern AC: Model predicting survival in stage I melonoma based on tumor progression. J Natl Cancer Inst 81: 1893-1904, 1989.
22. Woodruff M: Cellular Variation and Adaptation in Cancer. New York, Oxford University Press, 1990.
23. Luesley DM, Chan KK, Lawton FG, Blackledge GR and Mould JM: Survival after negative second-look laparotomy. Eur J Surg Oncol 15: 205-210, 1989.
24. Luesley D, Finn C and Varma R: The role of surgery in epithelial ovarian cancer. In: Ovarian Cancer 2 (Sharp F, Mason WP, and Creasman W, eds). London, Chapman & Hall, 1992, pp 357-367.
25. O'Reilly M, Rosenthal R, Sage EH, Smith S, Holmgren L, Moses M, Shing Y and Folkman J: The suppression of tumor metastases by a primary tumor. Surg Forum 44: 474-478, 1993.